OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Drug Discovery is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Lessons learned from phenotypic drug discovery efforts	184
Reality check: lipid-oligonucleotide conjugates for therapeutic applications	138
The root cause: why do so many drugs fail to translate from bench to bedside?	104
Scaffold hopping approaches for dual-target antitumor drug discovery: opportunities and challenges	83
Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery	62
What is the plausibility that all drugs will be designed by computers by the end of the decade?	54
Advances in ion channel high throughput screening: where are we in 2023?	53
Discovery of novel cathepsin K inhibitors for osteoporosis treatment using a deep learning-based strategy	52
γ-Secretase: once and future drug target for Alzheimer’s disease	45
Strategies for targeting RNA with small molecule drugs	44
Advances in the discovery of drugs that treat pulmonary arterial hypertension	43
Methods in marine natural product drug discovery: what’s new?	42
Tools and techniques for the discovery of therapeutic aptamers: recent advances	39
Bisquinoline as a promising scaffold in anti-infective drug discovery: the current state of the art and future prospects	38
The preclinical discovery and development of gepirone hydrochloride extended-release tablets: the first oral selective 5-HT1A receptor agonist for the treatment of major depressive disorder	37
A comprehensive update on the use of molecular topology applications for anti-infective drug discovery	36
Designing drugs against leishmaniasis: is targeting the sterol biosynthesis pathway the answer?	36
Phenotypic screening for new heart failure therapeutics: scalable animal modeling in zebrafish	35
Understanding the impact of binding free energy and kinetics calculations in modern drug discovery	35
Novel insights into structure–activity relationships of kynurenine 3-monooxygenase inhibitors (KMOis) with emphasis on chemical space, activity landscape exploration	34
A cautionary tale of paradox and false positives in cannabidiol research	32
The impact of antisense oligonucleotide (ASO) therapeutics on the future of rare disease drug discovery	32
C. elegans : a prominent platform for modeling and drug screening in neurological disorders	32
The potential of microfluidic platforms for neuron differentiation and pain modeling in novel drug discovery	31
The rules often neglected in current medicinal chemistry	31

Calcium channel blockers’ contribution to overcoming Current drug discovery challenges in Alzheimer’s disease	30
Water in drug design: pitfalls and good practices	30
Acoustic ejection mass spectrometry: fundamentals and applications in high-throughput drug discovery	29
An update on knowledge graphs and their current and potential applications in drug discovery	29
Virtual screening: hope, hype, and the fine line in between	29
Molecular hybridization: a powerful tool for multitarget drug discovery	29